Tag - QLGN

Developments

Qualigen posts positive readout in triple negative breast cancer in vivo model

Qualigen Therapeutics (NASDAQ:QLGN) completed its in vivo efficacy analysis of QN-247 in solid tumors, with data demonstrating robust efficacy and no safety signals in a triple negative breast cancer (TNBC) model...

August 2, 2022

Developments

Qualigen acquires majority stake in NanoSynex

Qualigen Therapeutics (NASDAQ:QLGN) completed the acquisition of a majority stake in NanoSynex, an Israeli-based developer of next generation diagnostics technology. In a statement, Michael Poirier, chairman and CEO of...

June 2, 2022

Feature

Qualigen advancing platform technologies in therapeutics and diagnostics

Backed by a commercial diagnostics business, Qualigen Therapeutics (NASDAQ:QLGN) has broadened its focus to developing platform therapeutics for cancer with potential orphan drug designation.

May 10, 2022

Executive Moves

Qualigen Therapeutics names Shishir Sinha to lead diagnostics division

Shishir Sinha Qualigen Therapeutics (NASDAQ:QLGN) appointed Shishir Sinha, the company’s newly promoted SVP and current COO, to lead its diagnostics division, FastPack. “With the return of the sales and...

April 29, 2022

Tag - QLGN

Qualigen posts positive readout in triple negative breast cancer in vivo model

Qualigen acquires majority stake in NanoSynex

Qualigen advancing platform technologies in therapeutics and diagnostics

Qualigen Therapeutics names Shishir Sinha to lead diagnostics division

General

More